Immutep Limited — Form 20-F Summary
Reporting period: Fiscal year ended June 30, 2019. Although the request metadata identifies “2018 Q4,” this filing is an annual report for FY2019, not a quarterly filing. Financial amounts below are in Australian dollars (A$), unless noted otherwise. The company reports under IFRS.
Business context
Immutep is a clinical-stage biotechnology company developing LAG-3-based immunotherapies for cancer and autoimmune diseases. Its lead candidate, eftilagimod alpha (efti/IMP321), was being evaluated in several combination trials. Other candidates include IMP761, IMP701 and IMP731; development of IMP701 and IMP731 is led by partners Novartis and GSK, respectively. Immutep had no approved products or material product-sales revenue and employed 24 people at year-end.
Financial performance and position
| Metric | FY2019 / June 30, 2019 | FY2018 / June 30, 2018 |
|---|---|---|
| License revenue | A$0.14 million | A$2.63 million |
| Other income | A$7.35 million | A$4.72 million |
| Research and development and intellectual property expense | A$16.59 million | A$9.99 million |
| Corporate administrative expense | A$6.37 million | A$7.24 million |
| Net loss | A$18.34 million | A$12.75 million |
| Basic and diluted loss per share | A$0.0057 loss per share (0.57 cents) | A$0.0049 loss per share (0.49 cents), restated |
| Net cash used in operating activities | A$15.29 million | A$7.78 million |
| Cash and cash equivalents | A$16.57 million | A$23.48 million |
| Total assets / total liabilities | A$40.54 million / A$16.15 million | A$47.00 million / A$13.48 million |
| Net assets | A$24.39 million | A$33.52 million |
Other income included A$4.34 million of government R&D grants, A$1.16 million of research-material sales, A$0.40 million of interest income, a A$0.49 million foreign-exchange gain and a A$0.96 million gain from warrant fair-value movements. These items, particularly grants and fair-value changes, are not recurring product sales. Operating margins are not meaningful for this loss-making development-stage business.
Current assets were A$23.54 million and current liabilities A$5.30 million at year-end. The balance sheet included a A$7.64 million convertible-note liability and a A$3.16 million warrant liability. The convertible notes had a stated face value of approximately A$13.75 million, a 3% coupon and an August 2025 maturity; their contractual undiscounted cash flows were reported as A$17.88 million. The filing reports no material contingent liabilities.
Changes versus the prior year
- License revenue fell by A$2.49 million, primarily because partner milestone receipts were lower than in FY2018.
- R&D and intellectual-property expense rose by A$6.60 million, mainly from expanded clinical activity, particularly AIPAC and TACTI-002.
- Net loss widened by A$5.60 million, reflecting higher R&D spending and lower license revenue.
- Operating cash outflow increased by A$7.51 million. Cash declined by A$6.91 million, notwithstanding A$8.01 million of net financing inflows.
- Corporate administrative expense decreased by A$0.88 million, largely due to lower employee share-based payment expense.
- Shares outstanding increased from 3.03 billion to 3.39 billion during FY2019. Historical EPS figures were restated for the bonus element of shares issued in the year.
Outlook, developments and risks
- Management expected cash resources to fund operations for more than 12 months from the filing date, while acknowledging substantial continuing losses and the need for additional funding. After year-end, Immutep raised A$10 million through a placement and entitlement offer, completed by August 6, 2019.
- Management expected R&D spending to increase as trials progressed; TACTI-002 costs could rise further if response results warranted expansion of a cohort. The filing provides no numerical earnings or revenue guidance.
- AIPAC completed recruitment of 227 randomized-phase patients in June 2019; first data were expected in calendar Q1 2020. TACTI-002 began dosing in March 2019 and had 26 participants reported by August. TACTI-mel final data were expected in calendar Q4 2019.
- In September 2019, GSK-triggered dosing in its Phase II ulcerative-colitis study qualified Immutep for a £4 million milestone payment, reported as approximately A$7.39 million. This was a post-year-end event, not FY2019 revenue.
- Key risks include clinical-trial failure or delay, regulatory and manufacturing hurdles, reliance on collaborators and contractors, patient-enrollment challenges, competition, intellectual-property disputes, foreign-exchange exposure and the possibility that further financing may be unavailable or dilutive. The company had no marketed products and had incurred recurring operating losses and negative operating cash flows.
- The company stated that it was a going concern and that directors expected it to meet obligations for at least 12 months from the financial-statement date, taking account of the subsequent financing. It had never paid dividends and did not expect to do so in the foreseeable future.
Important facts for investors to verify
- Confirm the subsequent A$10 million financing and £4 million GSK milestone receipt, including timing, cash collection and any conditions.
- Track trial results and milestones—especially AIPAC, TACTI-002, TACTI-mel and partner-led programs—and assess whether reported response signals translate into controlled, durable clinical benefit.
- Reconcile cash runway against the FY2019 operating cash outflow, planned trial spending, grants receivable and further funding needs.
- Review the convertible-note terms and fair-value accounting, warrant overhang and potential dilution from outstanding options, warrants and performance rights.
- Assess the quality and sustainability of other income, particularly government R&D incentives, partner milestones and non-cash fair-value gains.
- Note that PwC gave an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting at June 30, 2019; the auditor did not provide an internal-control attestation because Immutep was an emerging growth company.